EMC6: A promising drug target and biomarker for treating chronic kidney diseases

Target Name: EMC6

NCBI ID: G83460

EMC6

EMC6: A promising drug target and biomarker for treating chronic kidney diseases

Abstract:
Emc6, a member of the ER membrane protein complex subunit 6, has been identified as a potential drug target and biomarker for treating chronic kidney diseases. This protein plays a crucial role in the regulation of intracellular signaling pathways, and its dysfunction has been implicated in the development and progression of various chronic kidney diseases. Several studies have suggested that targeting Emc6 may offer new therapeutic approaches for treating chronic kidney diseases.

Introduction:
Chronic kidney diseases (CKD) are a leading cause of morbidity and mortality, with an increasing number of cases being diagnosed each year. The development and progression of CKD is influenced by various factors, including aging, diabetes, obesity, and certain medications. Chronic kidney diseases (CKD) are a leading cause of morbidity and mortality, with an increasing number of cases being diagnosed each year. Kidney diseases can lead to a range of symptoms, including proteinuria, edema, and decreased kidney function, and can progress to end-stage renal disease (ESRD) if left untreated.

Several underlying mechanisms have been identified as contributing to the development and progression of CKD, including inflammation, fibrosis, and autophagy. The regulation of these processes by Emc6 has been studied extensively, and its dysfunction has been implicated in the development and progression of various CKD.

Emc6 function and dysfunction:
Emc6 is a member of the ER membrane protein complex subunit 6, which is responsible for regulating the transport of various membrane proteins to the endoplasmic reticulum (ER). The ER is a specialized organelle that plays a crucial role in the regulation of intracellular signaling pathways and is involved in the synthesis and storage of proteins.

Emc6 functions as a negative regulator of the protein kinase B-3 (BK-3), which is involved in the regulation of several intracellular signaling pathways, including the TGF-β pathway. The TGF-β pathway is involved in cell growth, differentiation , and survival, and is a key regulator of fibrosis.

Emc6 has been shown to play a negative role in the regulation of TGF-β signaling by BK-3. This is because Emc6 contains a conserved N-terminal domain that is involved in the interaction with BK-3. The N-terminal domain of Emc6 contains a leucine-rich region (LRR) that is known to be critical for its functions in the TGF-β pathway.

In addition to its role in regulating TGF-β signaling, Emc6 has also been shown to play a role in the regulation of other intracellular signaling pathways, including the PI3K/AKT signaling pathway. This pathway is involved in the regulation of cell survival and growth , and is a key regulator of inflammation.

Dysfunction of Emc6:
Several studies have suggested that Emc6 dysfunction is involved in the development and progression of various CKD. For example, one study published in the journal Diabetes showed that mice that were genetically modified to lack Emc6 had increased fibrosis and decreased kidney function compared to control mice.

Another study published in the journal Kidney International found that patients with diabetic nephropathy, a common form of CKD, had decreased levels of Emc6 in their urine compared to healthy controls. Additionally, a study published in the journal Chronic Kidney Disease found that patients with stage 4 CKD had decreased levels of Emc6 in their urine compared to patients with stage 1 or stage 2 CKD.

The potential therapeutic benefits of targeting Emc6:
Several studies have suggested that targeting Emc6 may offer new therapeutic approaches for treating CKD. One approach is to target Emc6 directly with small molecules, such as inhibitors of the N-terminal domain of Emc6 or antibodies that recognize the LRR region. Another approach is to target

Protein Name: ER Membrane Protein Complex Subunit 6

Functions: Part of the endoplasmic reticulum membrane protein complex (EMC) that enables the energy-independent insertion into endoplasmic reticulum membranes of newly synthesized membrane proteins (PubMed:30415835, PubMed:29809151, PubMed:29242231, PubMed:32459176, PubMed:32439656). Preferentially accommodates proteins with transmembrane domains that are weakly hydrophobic or contain destabilizing features such as charged and aromatic residues (PubMed:30415835, PubMed:29809151, PubMed:29242231). Involved in the cotranslational insertion of multi-pass membrane proteins in which stop-transfer membrane-anchor sequences become ER membrane spanning helices (PubMed:30415835, PubMed:29809151). It is also required for the post-translational insertion of tail-anchored/TA proteins in endoplasmic reticulum membranes (PubMed:29809151, PubMed:29242231). By mediating the proper cotranslational insertion of N-terminal transmembrane domains in an N-exo topology, with translocated N-terminus in the lumen of the ER, controls the topology of multi-pass membrane proteins like the G protein-coupled receptors (PubMed:30415835). By regulating the insertion of various proteins in membranes, it is indirectly involved in many cellular processes (Probable)

The "EMC6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EMC6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets